ACADIA PHARMACEUTICALS INC 4

4 · ACADIA PHARMACEUTICALS INC · Filed Nov 13, 2015

Form 4

Period: 2015-11-11

Director

Transactions

Exercise/Conversion
Common Stock
2015-11-11$9.04/sh+6,000$54,240→ 42,127 total
Exercise/Conversion
Common Stock
2015-11-11$9.04/sh+10,000$90,400→ 52,127 total
Exercise/Conversion
Common Stock
2015-11-11$9.04/sh+9,126$82,499→ 61,253 total
Exercise/Conversion
Common Stock
2015-11-11$1.75/sh+4,874$8,530→ 66,127 total
Sale
Common Stock
2015-11-11$36.01/sh−30,000$1,080,327→ 36,127 total
Exercise/Conversion
Stock option (right to buy)
2015-11-11−6,000→ 0 total
Exercise: $9.04Exp: 2016-06-12→ Common Stock (6,000 underlying)
Exercise/Conversion
Stock option (right to buy)
2015-11-11−10,000→ 0 total
Exercise: $9.04Exp: 2016-06-12→ Common Stock (10,000 underlying)
Exercise/Conversion
Stock option (right to buy)
2015-11-11−9,126→ 0 total
Exercise: $9.04Exp: 2016-06-12→ Common Stock (9,126 underlying)
Exercise/Conversion
Stock option (right to buy)
2015-11-11−4,874→ 33,697 total
Exercise: $1.75Exp: 2021-06-09→ Common Stock (4,874 underlying)

Footnotes (4)

[F1]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in September 2015.
[F2]The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $35.67 to $36.44 per share, inclusive. The reporting person undertakes to provide ACADIA Pharmaceuticals Inc., any security holder of ACADIA Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the foregoing range.
[F3]25% of the shares subject to the Stock Option vested and became exercisable at the end of each 3-month period following the grant date of June 13, 2006.
[F4]25% of the shares subject to the Stock Option vested and became exercisable at the end of each 3-month period following the grant date of June 10, 2011.

Documents

1 file